Board of Directors

Asceneuron’s board members have a longstanding track record in building and overseeing highly successful biotechnology companies.

Our Board members have helped build some of the world’s most recognizable biotechnology companies. They provide strategic leadership to Asceneuron.

Abbas Hussain

Chairman of the Board

record of building and growing businesses across the Globe. He has a strong track record across the pharmaceutical value chain in both Mature and Emerging Markets. 

From July 2021 to January 2023, Abbas was CEO of Vifor Pharmaceuticals– a Swiss listed Nephrology focused Specialty Pharma company which was acquired in 2022 for circa $12Bn in one of the largest health care deals of the year.

Abbas currently holds various Non-Executive Director and Advisor roles including Alfasigma SpA, 4Bio Capital, C-Bridge Capital, Asceneuron SA, and GLG Institute.  He previously held various Non-Executive Director roles including Cochlear Limited, CSL, Teva Pharmaceutical, Immunocore and advisory roles with companies such as Hikma Plc, Cell Research Corp, Abingworth and Indegene Inc.  Abbas provides ad hoc consultancy services to PE and VC. 

Prior to his current portfolio of Non-Executive Director roles, Abbas was at GlaxoSmithKline for over ten years.  During his tenure at GlaxoSmithKline, Abbas was a member of the Corporate Executive Team and a Non-Executive Director of ViiV Healthcare. In December 2014, Abbas was appointed President, Global Pharmaceuticals with responsibilities for the Pharmaceuticals operations Europe, US and Emerging Markets & Asia.  

Prior to GlaxoSmithKline, Abbas was President, Europe at Eli Lilly and before that Vice President, Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions.  Abbas joined Lilly UK in 1988 and took on roles of increasing responsibility in Sales, Marketing and Business Development before his appointment as Managing Director of Turkey in 1998.  He then became General Manager, Lilly Deutschland.

Abbas is married to Susan and has 3 children.

Henrijette Richter

Director, Sofinnova Partners

Henrijette Richter is managing partners and an active member of the Capital Funds team at Sofinnova.

She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, Nodthera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.

Henrijette was attracted by Sofinnova Partners’ focus on a positive, consensus-oriented environment and its philosophy of investing in people.

Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).

Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.

Barbara Angehrn Pavik

Chief Executive Officer

With over two decades of expertise in the pharmaceutical and biotech industry, Barbara Angehrn Pavik is a highly experienced pharma and biotech executive. In her most recent position at Vifor Pharma Group, Barbara served as Executive Vice President and Chief Business Officer, overseeing a spectrum of global commercial and operational functions. Notably, Barbara played a key role in the company's acquisition by CSL Limited.

Throughout her career, she has assumed leadership roles in prominent EU and US companies, including EXELIXIS, ONYX PHARMACEUTICALS, and AMGEN. Barbara also founded and served as the Chief Executive of STEPSTONE Pharma.
Beyond her executive capacities, Barbara currently holds Non-Executive Board Director positions at BELLEVUE Group, a healthcare focused asset management organization, and at medmix, a global leader in high-precision devices.
Barbara completed her education, earning a Bachelor & Master in Business Administration from the University of St. Gallen, Switzerland.

Hakan Goker

Director, M Ventures

Hakan Goker (Ph.D.) is a senior investment director at M Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan joined M Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of  multiple biotechnology companies globally including Asceneuron (CH), Orphazyme (DK), Nimbus Discovery (US), F Star (NL), Bicycle Therapeutics (UK) and Nitec now Horizon Pharma (CH/US).
Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Asceneuron, Artios Pharma, Forendo, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.

Amit Shah, MD

Director, SR One

Amit is a Principal in SR One London office and covers venture capital investments in biotech. Prior to joining SR One in early 2018, Amit worked in various roles at GlaxoSmithKline including late phase clinical development, global med affairs, and early pipeline commercial strategy. He is a board certified equivalent plastic surgeon, specialised in microsurgical cancer reconstruction. Since 2020, Amit has sat on the venture capital panel for the BioInnovation Institute, Novo Nordisk’s international life sciences incubator.

Lior Teitelbaum

Director, Johnson & Johnson Innovation -JJDC

Lior Teitelbaum is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc., where he is responsible for investments in the MedTech, Pharmaceutical, and Biotechnology spaces across Israel/Europe. He brings over 17 years of experience in founding, financing and operating in early-stage life sciences companies.

Prior to joining JJDC, Lior was the CBO of FutuRx, a JJDC associated Biotech company creation incubator, where he was responsible for all search & evaluation, transaction and company creation activities as well for FutuRx’s SAB management. He was also responsible for Business Development activities and fundraising for all of the FutuRx portfolio companies and for all BD activities of the FutuRx incubator. Before that Lior cofounded the first digital health incubator in Israel supported by Medtronic and IBM.
Prior to that Lior held multiple BD , transaction and alliance management leadership roles in public and private Biotech and Medtech companies. Lior holds an MSc in Molecular Genetics from the Weizmann Institute of science and an MBA from the Tel Aviv University.

Catherine Moukheibir

Independent Director

Ms. Moukheibir most recently served as chief executive officer of MedDay Pharmaceuticals, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chairman of the board of directors of MedDay from April 2016 to January 2021. Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to December 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.

Ms. Moukheibir currently serves on the board of directors and chairs the audit committee of Biotalys, Orphazyme A/S, Ironwood Pharmaceuticals and CMR Surgical. She also held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA, Creabilis S.A., GenKyoTex S.A., Kymab Group Ltd and Zealand Pharma A/S.  She has an M.A. in economics and an M.B.A. from Yale University.  Ms. Moukheibir’s long leadership career in the biopharmaceutical industry, as well as her deep background in international finance, provide her with valuable business and financial expertise in support of our corporate objectives.

 

Eric Yuen

Non-executive Director

Dr Eric Yuen, has over 25 years of clinical development experience in central nervous system (CNS) pathologies and has led multiple Phase I-IV development programs for biologics and small molecules obtaining numerous regulatory approvals. He is currently Chief Medical Officer at Talee Bio Inc which he co-founded in addition to RiboNova Inc. He has held senior positions in several biotech companies including as Chief Medical Officer at Inozyme Pharma and Ultragenyx Pharmaceuticals.

Dr Yuen received his M.D. from the Pritzker School of Medicine at the University of Chicago and completed his neurology training at the University of California at San Francisco. He holds a B.S. in Physics and Biology with Academic Distinction from Stanford University.

  • $

    Investors

  • $

    Management Team

  • $

    Pipeline